Abstract

Liver disorders in children will affect the pharmacokinetics and pharmacodynamics of drugs that are metabolized in the liver. Chronic liver disease in children such as chronic hepatitis, cirrhosis of the liver can affect the absorption and disposition (pharmacokinetics) of drugs and the efficacy and safety (pharmacodynamics) of drugs in the body. Dosage modification is determined based on clinical studies examining the effects of impaired liver function on the pharmacodynamics and pharmacokinetics of a drug.

Highlights

  • Metabolism and elimination of drugs in our body can be carried out in various ways and is carried out by various organs, including the liver, intestinal walls, kidneys, blood plasma

  • High clearance drugs mean that these drugs are metabolized primarily in the liver, so that the metabolic process and elimination of these drugs are strongly influenced by hepatic drug clearance

  • Liver disorders in children will affect the pharmacokinetics and pharmacodynamics of drugs that are metabolized in the liver

Read more

Summary

Introduction

Metabolism and elimination of drugs in our body can be carried out in various ways and is carried out by various organs, including the liver, intestinal walls, kidneys, blood plasma. Hepatic drug clearance is affected by both hepatic blood flow and liver enzyme function. There will be changes in blood flow and liver enzyme activity, thereby reducing hepatic drug clearance, which will affect drugs with intermediate and high hepatic extraction ratios. This condition will increase the concentration of circulating and non-binding drugs in the blood. 3. Drug use and dosage modification To date, no universal marker has been found to predict drug elimination in the body. The Child-Pugh classification is often used, the original aim of this classification was to predict one- and two-year survival in patients with impaired liver function

Mild to moderate Severe
PB Recommendations
Dosage adjustment recommendations
Must be extra careful with drugs with a low therapeutic index
Initiation of administration at normal dose
Findings
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.